As shown in Figure 6A, the 10-year overall survival rate of the four ROS1-translocated adenocarcinoma patients was worse than that of patients without ROS1 translocation in the pre-crizotinib period (p < 0.0001). This evidence concerns the gene ROS1 and adenocarcinoma.